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Abstract 
Background: Bladder cancer (BCa) is among the most commonly diagnosed malignancies worldwide, and due the 
high rate of post-operative disease recurrence, it is one of the most prevalent in many countries. The development 
of non-invasive molecular assays that can accurately detect and monitor BCa would be a major advance, benefiting 
both patients and healthcare systems. We have previously identified a urinary protein biomarker panel that is being 
developed for application in at-risk patient cohorts. Here, we investigated the potential utility of the multiplex assay in 
a Japanese cohort.
Methods: The Japanese study cohort collected from urology clinics at two institutions was comprised of a total 
of 288 subjects. The protein biomarker panel (IL8, MMP9, MMP10, ANG, APOE, SDC1, A1AT, PAI1, CA9, VEGFA) was 
monitored in voided urine samples collected prior to cystoscopy using a custom multiplex ELISA assay. The diagnostic 
performance of the biomarker panel was assessed using receiver operator curves, predictive modeling and descrip-
tive statistics.
Results: Urinary biomarker concentrations were significantly elevated in cases versus controls, and in cases with 
high-grade and muscle-invasive tumors. The AUC for the 10-biomarker assay was 0.892 (95 % confidence interval 
0.850–0.934), with an overall diagnostic sensitivity specificity of 0.85 and 0.81, respectively. A predictive model trained 
on the larger institutional cohort correctly identified 99 % of the cases from the second institution.
Conclusions: Urinary levels of a 10-biomarker panel enabled discrimination of patients with BCa. The multiplex 
urinary diagnostic assay has the potential to be developed for the non-invasive detection of BCa in at-risk Japanese 
patients.
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Background
Bladder cancer (BCa) is a major burden for both patients 
and health care systems worldwide [1]. At initial pres-
entation, the majority of cases are non-muscle invasive 
tumors, which are not immediately life-threatening. 
However, more than 70  % of patients with operable 
BCa will have a recurrence during the first 2 years after 
diagnosis and the subsequent lesions can progress to 
being muscle invasive and metastatic [2]. Thus, once 
treated, BCa patients are under continual surveillance 
with routine cystoscopy examinations for early detection 
of new BCa development. Due to the prolonged natural 
history of BCa, plus the prolonged and invasive nature of 
follow-up and treatment strategies, it is one of the most 
expensive malignancies to manage on a per-patient basis 
[3]. Although Japan and other Asian countries have a 
somewhat lower incidence of BCa than Europe and the 
Americas, the clinico-pathological characteristics of the 
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newly diagnosed and 5000 patients die from the disease 
annually. While the overall incidence trend has been rela-
tively stable over the past decade [4, 5], because the onset 
is most often seen in elderly patients, it is becoming a 
major social issue in an aging Japanese society.
In a series of previous studies, we have identified pan-
els of protein biomarkers that are significantly associated 
with BCa [6, 7]. Through several studies [8–10] we have 
refined the target composition, and the immunoassay 
approach [11], in order to develop a viable non-invasive 
assay for BCa detection. In this study, we tested the poten-
tial utility of the multiplex immunoassay for the detection 
of BCa in a Japanese cohort. Evaluation of 288 subjects 
obtained from two independent institutes confirmed a 
significant association of the tested biomarkers with the 
presence of BCa. The multiplex assay achieved a strong 
overall diagnostic performance achieving 85 % sensitivity 
and 81 % specificity (AUC 0.892). This retrospective phase 
II study confirms the potential of using urinary protein 
biomarker signatures for the non-invasive detection of 
BCa, and suggests that the described multiplex immuno-
assay could aid in Japanese urology patient management.
Methods
Patients and specimen processing
Under Western Institutional Review Board approval 
(IRB #Rosser 2014-1), previously collected and banked 
voided urine samples shipped to University of Hawaii 
Cancer Center for analysis. Originally, voided urine sam-
ples were collected prior to cystoscopy, and stored frozen 
until analysis. The study cohort (Table 1) was comprised 
of subjects from two independent institutions; the Kyoto 
cohort consisted of 80 subjects with newly diagnosed 
BCa, and 67 subjects with no active BCa (controls) 
including subjects with voiding symptoms, renal or pros-
tate cancer, urinary tract infections or urolithiasis. The 
Nara cohort consisted of 131 subjects with newly diag-
nosed BCa. For the bladder cancer case group, histologi-
cal confirmation of urothelial carcinoma, including grade 
and stage was defined from excised tissue. Frozen ali-
quots of urine samples were thawed and protein content 
was measured using a Pierce 660-nm Protein Assay Kit 
(Thermo Fisher Scientific Inc., Waltham, MA, USA). The 
concentration of urinary creatinine was measured using 
a commercially available enzymatic assay (Cat#KGE005 
R&D Systems Inc., Minneapolis, MN, USA) according to 
the manufacturer’s instructions. Normalization to creati-
nine is the standard means of expressing analytes in urine 
to minimize the impact of patient hydration status [12].
Multiplex immunoassay
The concentrations of the 10 proteins (IL8, MMP9, 
MMP10, ANG, APOE, SDC1, A1AT, PAI1, CA9 and 
VEGFA) were monitored using a custom multiplex 
immunoassay using MULTI-ARRAY® technology (Meso 
Scale Diagnostics, LLC, Rockville, MD). The multiplex 
assay, using MULTI-SPOT® plates, is based on a proprie-
tary combination of electrochemiluminescence detection 
and patterned arrays [13–15]. Final monoclonal antibody 
pairs (capture and detection) were selected based on sen-
sitivity, specificity, physical properties, and recognition 
of native protein, as described previously [11]. In order 
to ensure detection across the range of protein concen-
trations, 7 of the 10 assays (IL8, MMP9, MMP10, APOE, 
PAI1, CA9 and VEGFA) were multiplexed in one well, 
and the other 3 assays (ANG, SDC1, A1AT) in a separate 
well. Urine samples were diluted fourfold for the 7-plex 
assay and 200-fold for the 3-plex assay. A seven point 
standard curve across the 4 log dynamic range of the 
assays was included in the current assay design. Urine 
samples were handled on ice and diluted with MSD 
Assay Diluent 37 [11]. Samples and standards (50  μl) 
were added to the plate and incubated for 2  h at RT. 
After washing, SULFO-TAG conjugated detection anti-
body mix (25 μl) was added and incubated for 2 h at RT. 
After washing, the ensuing immunoassay complex was 
incubated with MSD Read Buffer (150  μl) and electro-
chemiluminescence measured on the QuickPlex® SQ 120 
(MSD) instrument. Standard curves were constructed 
using MSD Discovery Workbench® 4.0, which allows 
for the selection of multiple non-linear and linear equa-
tions to fit the standard curve. Optimal curve fits were 
determined by visual graph evaluation and comparison of 
akaike’s information criteria (AIC) values [16].






Median age (range, years) 75 (22–95) 70 (30–90)
Male:female ratio 183/28 53/14
Stage n/a 
 NMIBC 170 (80.6 %)
 MIBC 41 (19.4 %)
Grade n/a 
 Low 87 (41.2 %)
 High 124 (58.8 %)
Clinical stage n/a 
 Tis high-grade 7 (3.3 %)
 Ta low-grade 80 (37.9 %)
 Ta high-grade 29 (13.7 %)
 T1 low-grade 7 (3.3 %)
 T1 high-grade 47 (22.3 %)
 ≥T2 high-grade 41 (19.4 %)
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Data analysis
Wilcoxon rank sum tests were used to determine the 
association between each biomarker and BCa. Nonpara-
metric receiver operating characteristic (ROC) curves 
were generated to plot assay sensitivity against the false-
positive rate (1-specificity). The relative ability of each 
biomarker to indicate BCa was evaluated by calculating 
the area under the curve (AUC), and AUCs were com-
pared by Chi-square test. The sensitivity and specificity 
of each biomarker and their combinations were estimated 
at the optimal cutoff value defined by the Youden index 
[17]. Furthermore, the formula for calculating the com-
bined score of prediction was −3.3600  +  (0.4889)*nor-
malized IL8 + (−2.9371)*normalized MMP9 + (0.2112)* 
normalized A1AT  +  (−0.0470)*normalized ANG  +   
(−0.5617)*normalized VEGFA  +  (1.7788)*normalized 
CA9 + (−0.1412)*normalized MMP10 + (−3.0268)*nor-
malized APOE  +  (47.5054)*normalized PAI1  +   
(7.4465)*normalized SDC1  >  0.80385). To assess the 
independent association between biomarkers and BCa, 
we used logistic regression analysis with BCa status (yes 
vs. no) as the response variable and biomarker concen-
trations as explanatory variables. Multiple-level logistic 
regression was used to evaluate biomarker association 
with tumor grade and muscle-invasive disease. The all-
subset method was used to evaluate the predictive value 
of each possible combination of biomarkers, and the 
Bayesian information criterion (BIC) was used to com-
pare models. The BIC, a widely used criterion in model 
selection, balances the model likelihood and the number 
of biomarkers included in the model [18]. The Bootstrap 
method (using 1000 Bootstrap samples) was used [19] to 
select the most efficient and stable predictive model. Sen-
sitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) were calculated from 
ROC data. Statistical significance in this study was set at 
P < 0.05 and all reported P values were 2-sided. All analy-
ses were performed using SAS software version 9.4.
Results
Patient characteristics
Clinical, pathologic and demographic characteristics 
of the 288 subjects (183 BCa, 96 benign controls, and 
41 healthy volunteers) comprising the study cohort are 
listed in Table  1. Of the 211 bladder cancer cases, 170 
were classified as non-muscle invasive bladder cancer 
(NMIBC; stages Ta, Tis, T1), and 41 were muscle invasive 
bladder cancer (MIBC; stage ≥  T2). Eighty-seven cases 
were reported as low-grade carcinoma and 98 cases as 
high-grade. Gender distribution (BCa incidence is higher 
in men), and slightly older median age for patients in the 
BCa group reflect typical BCa incidence statistics [1].
Urinary biomarker levels and assay performance
Biomarker concentration data were normalized to uri-
nary creatinine [12] to adjust for urine volume variations 
and to be consistent with our previous studies [8–11]. 
Urinary concentrations of all 10 biomarkers were sig-
nificantly elevated in patients with bladder cancer com-
pared with controls (Table 2). The concentrations of 9 of 
the 10 biomarkers (except SDC1) were also significantly 
elevated in patients with high-grade BCa relative to low-
grade BCa, and MIBC relative to NMIBC (Table 2). The 
diagnostic performance of each individual biomarker 
was analyzed using nonparametric ROC analyses [20]. 
As observed previously, many of the individual biomark-
ers achieved respectable diagnostic performance values, 
with SDC1 and SERPINA1 both recording AUC values 
>0.80. Table  3 provides AUC and corresponding sensi-
tivity, specificity, PPV, and NPV values for all biomark-
ers tested. The optimal test was derived by combination 
of the 10 biomarkers into a diagnostic panel. In line with 
our previous multi-institutional studies with cohorts 
from the USA and Europe [9, 10], the 10-biomarker 
assay achieved an AUC of 0.8925 in the Japanese cohort 
(Fig.  1), with an overall diagnostic sensitivity of 0.895 
and specificity of 0.806 (Table 3). As expected, sensitiv-
ity and specificity values of the combined assay (Table 4) 
were higher for high-grade (90.3/85.1  %) and for MIBC 
bladder cancer (85.4/95.5 %), but the overall performance 
was comparable. Although data was incomplete, voided 
urine cytology data indicated sensitivity values of ~45 % 
for those subjects tested in this cohort.
The overall classification data was obtained through 
analysis of data from the total cohort, but given that sub-
jects were combined from two independent institutes, 
we could also investigate the ability of a predictive model 
derived from one institute to identify cases in the second 
institute. The Kyoto cohort (147 subjects) had a balance 
of 80 cases and 67 controls, so this was used to build a 
predictive model. The best logistic regression model for 
the 10-biomarker panel correctly identified 56 of the 80 
Kyoto cases. Although this was less accurate than the 
overall classification analyses described above, when 
applied to the Nara cohort the Kyoto-derived predictive 
model correctly identified 130 of the 131 Nara cases as 
harboring BCa.
Discussion
Bladder cancer is among the most common worldwide 
malignancies, and due to the high recurrence rate, it is 
also one of the most burdensome for both patients and 
healthcare systems. Current guidelines for BCa diagno-
sis recommend cystoscopy coupled with voided urine 
cytology (VUC), but cystoscopy is an invasive procedure 
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associated with discomfort and anxiety, infection and 
trauma [21, 22]. Non-invasive VUC is used routinely as 
an adjunct to cystoscopy, but the subjective assay can be 
impaired by inter-observer variability and has poor sen-
sitivity, especially for low-grade and low-stage tumors 
[23, 24]. Urine-based, quantitative assays that can non-
invasively detect BCa would improve the rapid diagnosis 
of BCa and help to avoid unnecessary invasive cystos-
copy and biopsy procedures, however, while a number 
of such assays have been proposed, to date, such assays 
have lacked adequate accuracy to replace VUC, or to 
support or guide cystoscopy. The lack of accuracy of cur-
rent urinary tests may be due to the fact that they typi-
cally rely on measuring a single biomarker. A shift from 
single biomarker assays to multiplex molecular signa-
tures that reflect the molecular pathways of BCa provides 
an opportunity to develop assays with clinical utility 
across the breadth of disease states. The advent of high-
throughput technologies has facilitated the discovery of 
more complex molecular signatures with diagnostic or 
prognostic potential, and a number of gene expression 
signature assays are now being incorporated into clinical 
practice [25, 26].
Through proteomic profiling of naturally micturated 
urine, we were able to identify a set of urinary proteins 
that were associated with the presence of BCa [6, 7]. One 
advantage of profiling the urine component directly is 
the ability to compare samples collected from subjects 
with non-malignant conditions, a situation that is not 
feasible using surgically excised solid tissue samples. The 
candidate biomarkers were refined through independent 
validation studies [27, 28], and a 10-biomarker panel was 
established for development. The diagnostic performance 
of the 10-protein assay was then tested in two independ-
ent cohorts, one [9] comprised of 127 subjects (diagnos-
tic sensitivity of 92 %, specificity of 97 %), and one [10] 
comprised of 308 patients obtained from multiple insti-
tutions in the USA and Europe (sensitivity 74  %, speci-
ficity 90  %). Taken together, these studies illustrate the 
reproducibility of the diagnostic protein panel in terms 
of a robust biomarker panel that achieved similar perfor-
mance data across multiple, independent cohorts. Based 
on these results, we investigated the feasibility of devel-
oping a multiplex assay that could accurately and simulta-
neously monitor the diagnostic biomarkers in an efficient 
format for potential clinical application. A custom-
designed multiplex assay using MULTI-ARRAY® tech-
nology (meso scale diagnostics, LLC) was constructed, 
and the analytical performance was compared with data 
obtained from individual ELISA assays directed at each 
of the same 10 urinary proteins. The multiplex assay 
achieved excellent concordance, and improved detection 
range and technical sensitivity [11]. The diagnostic per-
formance of the assay was confirmed in an independent 
cohort of 200 subjects (sensitivity 85 %, specificity 81 %). 
The integration of multiplex molecular signatures into a 
single assay is beneficial for clinical translation through 
reduced sample volume, decreased processing time, 
low cost analysis and low reagent consumption, and the 
MULTI-ARRAY® assay can be readily implemented into 
a CLIA certified laboratory setting using existing instru-
mentation and skillsets.
Table 2 Mean urinary (±SD) concentrations of ten biomarkers assessed by ELISA in cohort of 288 subjects
NMIBC non-muscle invasive bladder cancer, MIBC muscle invasive bladder cancer
a  P < 0.05 comparing total bladder cancer to total controls
b  P < 0.05 comparing low-grade bladder cancer to high-grade bladder cancer
c  P < 0.05 comparing NMIBC to MIBC







(75.9 %) (41.2 %) (58.8 %) (80.6 %) (19.4 %) (24.1 %)
n = 211 n = 87 n = 124 n = 170 n = 41 n = 67
IL8 (pg/mL)abc 1.224 ± 1.387 0.763 ± 0.824 1.547 ± 1.598 1.020 ± 1.177 2.070 ± 1.826 0.566 ± 0.464
MMP9 (ng/mL)abc 0.485 ± 0.536 0.311 ± 0.261 0.607 ± 0.638 0.411 ± 0.434 0.792 ± 0.770 0.319 ± 0.366
SERPINA1 (ng/mL)abc 2.648 ± 2.538 1.891 ± 1.594 3.180 ± 2.920 2.312 ± 2.147 4.041 ± 3.444 1.061 ± 0.711
ANG (pg/mL)abc 2.133 ± 1.181 1.812 ± 0.928 2.358 ± 1.286 1.979 ± 1.037 2.770 ± 1.504 1.190 ± 0.543
VEGF (pg/mL)abc 1.852 ± 1.021 1.570 ± 0.610 2.050 ± 1.193 1.731 ± 0.897 2.352 ± 1.322 1.386 ± 0.395
CA9 (pg/mL)abc 0.770 ± 0.971 0.577 ± 0.480 0.905 ± 1.185 0.668 ± 0.805 1.190 ± 1.411 0.357 ± 0.242
MMP10 (pg/mL)abc 0.989 ± 1.625 0.626 ± 0.422 1.243 ± 2.055 0.814 ± 1.346 1.713 ± 2.353 0.517 ± 0.492
APOE (pg/mL)abc 0.639 ± 0.427 0.491 ± 0.307 0.744 ± 0.468 0.571 ± 0.373 0.923 ± 0.518 0.420 ± 0.177
SERPINE1 (ng/mL)abc 0.156 ± 0.181 0.096 ± 0.080 0.198 ± 0.217 0.125 ± 0.134 0.284 ± 0.273 0.056 ± 0.030
SDC1 (pg/mL)a 0.489 ± 0.140 0.468 ± 0.127 0.504 ± 0.147 0.478 ± 0.129 0.534 ± 0.172 0.331 ± 0.121
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Here, we extended the evaluation of the multiplex BCa 
diagnostic assay to a phase II, multicenter study with a 
cohort comprised of 288 Japanese subjects. For overall 
classification, the multiplex assay achieved a sensitivity 
of 84.8 % and specificity of 80.6 % (AUC of 0.892). Bio-
marker expression and assay performance increased with 
increasing tumor stage and grade. The results in the Jap-
anese cohort were very much in line with our previous 
studies evaluating cohorts from the USA and Europe [9–
11], but as we refine and optimize the technical aspects of 
the assay and analyze additional samples, we expect to be 
able to further improve assay performance. While subtle 
differences in composition of optimal urinary diagnostic 
protein panels may exist in cohorts comprised of differ-
ent ethnic populations, given the translation of an assay 
optimized in diverse cohorts to a Japanese population, 
these data are very encouraging, and further validate the 
concept that a multiplex panel of urinary protein bio-
markers can assist the noninvasive diagnosis of BCa.
We recognize that the study has a number of limita-
tions. The cohort was comprised of >50 % cases, but dis-
ease prevalence is typically considerably lower in routine 
urologic practice. While it was important to initially test 
enough cases to achieve statistical significance, it will 
be necessary to perform additional studies that reflect 
urology clinic presentation to assess predictive value 
of the assay. It will also be necessary to include more 
diverse controls that may be under-represented in our 
study cohort. To address these issues, we have launched 
a multi-institute, prospective clinical trial, which will 
assess the multiplex diagnostic assay in subjects with 
gross hematuria, microscopic hematuria and history of 
BCa on tumor surveillance. Such a study would minimize 
selection bias, better represent urological disease preva-
lence, and evaluate potential confounding comorbidi-
ties in the study population. Furthermore, in this study, 
we focused only on subjects with primary BCa, however, 
we have previously reported that the multiplex assay is 
also accurate for the detection of recurrent BCa (sensi-
tivity 79  %, specificity 88  %), outperforming the Urovy-
sion cytogenetic assay and VUC [29]. The inclusion of 
Japanese patients on routine surveillance after primary 
BCa treatment will be an additional goal and will enable 
evaluation of potential prognostic utility of the assay. 
Finally, we have initiated the development of BCa diag-
nostic nomograms that incorporate biomarker data with 
relevant clinical information (e.g., age, sex, race, and 
tobacco history) in US cohort studies, and this can also 
be extended to future Japanese cohort studies.
Conclusion
Bladder cancer is a common neoplastic disease with a 
high rate of recurrence and progression, and the recur-
rence phenomenon makes it one of the most prevalent 
cancers worldwide. The development of robust non-
invasive, urine-based assay for the detection of BCa is 
clinically urgent. In this study, we have been able to suc-
cessfully translate a multiplex diagnostic assay derived 
from diverse cohort studies to the analysis of a Japanese 
population. The diagnostic assay achieved encouraging 
Fig. 1 Diagnostic performance of a multiplex protein biomarker 
assay. ROC was plotted to describe performance characteristics in a 
288 subject cohort. Area under the curve (AUC) 0.8925
Table 4 Summary of diagnostic sensitivity of 10-biomarker panel and voided urinary cytology in patients with bladder 
cancer
NMIBC non-muscle invasive bladder cancer, MIBC muscle invasive bladder cancer, AUC Area under ROC curve
No of bladder cancer cases  
predicted by biomarker assay
AUC Sensitivity (%) Specificity (%)
Overall 179 of 211 0.895 84.8 80.6
Low-grade tumors 63 of 87 0.849 72.4 82.1
High-grade tumors 112 of 124 0.932 90.3 85.1
NMIBC 139 of 170 0.878 81.8 80.6
MIBC 35 of 41 0.961 85.4 95.5
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performance values and will be the focus of ongoing stud-
ies to investigate the potential added value of the multi-
plex assay if integrated into clinical decision making.
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